----item----
version: 1
id: {E38F88CF-C4B3-40C4-9B71-8FE2971EBA11}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/03/13/Akzo Nobel reports 6 sales growth in 1994
parent: {DD133DA8-D39B-429A-976D-1571C2F017A8}
name: Akzo Nobel reports 6 sales growth in 1994
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: f3ae7230-2128-4dd9-a0ed-a8b1864f410b

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 670

<p>In the first full year after its merger, Dutch-Swedish chemicals and fibres group Akzo Nobel has reported a 6% increase in 1994 group turnover compared with the previous year and a 7% sales rise for its pharma division. The latter had revenues of Fl 3,669 million ($2,210 million). It includes diagnostics manufacturer Organon Teknika. Akzo Nobel in fact mentions Organon's international activities, along with Diosynth and Intervet, as contributors to the pharma division's growth last year. Stepped-up R&D efforts led to Fl 50 million higher spending, says Akzo Nobel. Operating income generated by the division was Fl 655 million, up 11% from a pro forma 1993.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 43

Akzo Nobel reports 6% sales growth in 1994:
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 842

<p>In the first full year after its merger, Dutch-Swedish chemicals and fibres group Akzo Nobel has reported a 6% increase in 1994 group turnover compared with the previous year and a 7% sales rise for its pharma division. The latter had revenues of Fl 3,669 million ($2,210 million). It includes diagnostics manufacturer Organon Teknika. Akzo Nobel in fact mentions Organon's international activities, along with Diosynth and Intervet, as contributors to the pharma division's growth last year. Stepped-up R&D efforts led to Fl 50 million higher spending, says Akzo Nobel. Operating income generated by the division was Fl 655 million, up 11% from a pro forma 1993.</p><pre>Revenues Net income (Fl millions) (Fl millions) 1994 1993* 1994 1993* 3 months 5,452 5,103 287 173 Year 22,208 20,874 1,178 790 (ended Dec 31st) * 1993 pro forma</pre>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 41

Akzo Nobel reports 6 sales growth in 1994
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950313T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950313T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950313T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT051835
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 43

Akzo Nobel reports 6% sales growth in 1994:
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253604
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T183959Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

f3ae7230-2128-4dd9-a0ed-a8b1864f410b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T183959Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
